Tweet
Shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) have received an average recommendation of "Buy" from the eleven brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $36.78.
A number of brokerages have recently issued reports on GLMD. HC Wainwright upped their price objective on shares of Galmed Pharmaceuticals from $24.00 to $43.00 and gave the company a "buy" rating in a research note on Tuesday, June 12th. ValuEngine raised shares of Galmed Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, June 12th. Maxim Group upped their price objective on shares of Galmed Pharmaceuticals from $14.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, June 12th. SunTrust Banks upped their price objective on shares of Galmed Pharmaceuticals from $15.00 to $31.00 in a research note on Tuesday, June 12th. Finally, Stifel Nicolaus began coverage on shares of Galmed Pharmaceuticals in a research note on Friday, July 13th. They issued a "buy" rating and a $35.00 price objective for the company. Get Galmed Pharmaceuticals alerts:
A number of large investors have recently bought and sold shares of GLMD. Vivo Capital LLC bought a new stake in Galmed Pharmaceuticals during the 2nd quarter valued at $9,433,000. Baker BROS. Advisors LP bought a new stake in Galmed Pharmaceuticals during the 2nd quarter valued at $7,570,000. Point72 Asset Management L.P. bought a new stake in Galmed Pharmaceuticals during the 2nd quarter valued at $7,449,000. Nantahala Capital Management LLC raised its holdings in Galmed Pharmaceuticals by 140.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 741,108 shares of the biopharmaceutical company's stock valued at $8,819,000 after buying an additional 432,480 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Galmed Pharmaceuticals by 1,768.2% during the 2nd quarter. Millennium Management LLC now owns 315,356 shares of the biopharmaceutical company's stock valued at $3,753,000 after buying an additional 298,476 shares during the last quarter. Institutional investors own 18.29% of the company's stock. Shares of Galmed Pharmaceuticals stock opened at $11.51 on Friday. Galmed Pharmaceuticals has a 52-week low of $3.61 and a 52-week high of $27.06. The firm has a market capitalization of $194.87 million, a PE ratio of -11.74 and a beta of 2.68.
Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by ($0.01). Galmed Pharmaceuticals had a negative net margin of 1,072.44% and a negative return on equity of 36.66%. The business had revenue of $0.27 million during the quarter, compared to analysts' expectations of $0.27 million. analysts forecast that Galmed Pharmaceuticals will post -0.59 earnings per share for the current fiscal year.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis